Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Biorestorative Therapies Inc
(NQ:
BRTX
)
1.580
UNCHANGED
Streaming Delayed Price
Updated: 3:58 PM EDT, Oct 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Biorestorative Therapies Inc
< Previous
1
2
3
4
5
6
Next >
BioRestorative Therapeutics (BRTX) Stock Soars 40% on Patent News
March 02, 2023
Could more patents translate to more revenue for BioRestorative Therapeutics? It's a question that BRTX stock traders are considering now.
Via
InvestorPlace
Wall Street Mixed At Open; US Weekly Jobless Claims Decline
March 02, 2023
U.S. stocks traded mixed this morning, with the Dow Jones gaining around 80 points on Thursday. Following the market opening Thursday, the Dow traded up 0.24% to 32,740.88 while the NASDAQ fell 0.58%...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
March 02, 2023
Via
Benzinga
EXCLUSIVE: BioRestorative To Receive Third US Patent For Metabolic ThermoStem Program
March 02, 2023
The United States Patent and Trademark Office has issued a notice of allowance for a patent application related to BioRestorative Therapies Inc's (NASDAQ: BRTX) metabolic ThermoStem program.
Via
Benzinga
BioRestorative Therapies: This Biopharma Company Is Helping Your Body Heal Itself
February 16, 2023
Lance Alstodt, Chairman and CEO of BioRestorative Therapies, Inc. (NASDAQ: BRTX), was recently interviewed by Benzinga.
Via
Benzinga
BioRestorative Therapies Inc (NASDAQ: BRTX) Announces European Patentability Of ThermoStem® Program With Indications In Obesity And Type 2 Diabetes
February 10, 2023
By Julian Richard, Benzinga
Via
TheNewswire.com
Topics
Intellectual Property
Exposures
Intellectual Property
BioRestorative Therapies Inc (NASDAQ: BRTX) Announces European Patentability Of ThermoStem® Program With Indications In Obesity And Type 2 Diabetes
February 10, 2023
BioRestorative Therapies Inc (NASDAQ: BRTX) Announces European Patentability Of ThermoStem® Program With Indications In Obesity And Type 2 Diabetes
Via
News Direct
Topics
Intellectual Property
Exposures
Intellectual Property
BioRestorative Therapies Inc (NASDAQ: BRTX) Announces European Patentability Of ThermoStem® Program With Indications In Obesity And Type 2 Diabetes
February 10, 2023
BioRestorative Therapies (NASDAQ: BRTX), a clinical-stage biotechnology company focused on stem cell-based therapies, announced on the 8th of February that the European Patent Office had issued a...
Via
Benzinga
BioMedNewsBreaks – BioRestorative Therapies Inc. (NASDAQ: BRTX) Eyes Continued Growth of Patent Family for ThermoStem(R) Program
February 08, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
EXCLUSIVE: BioRestorative Poised To Receive European Patent For ThermoStem Program
February 08, 2023
The European Patent Office has issued a notice of allowance for a patent application related to BioRestorative Therapies Inc's (NASDAQ: BRTX) metabolic ThermoStem program. The notice of allowance was...
Via
Benzinga
BioRestorative (NASDAQ: BRTX) Ramps Up Production In Anticipation Of Positive Phase 2 Results
February 03, 2023
BioRestorative (NASDAQ: BRTX) Ramps Up Production In Anticipation Of Positive Phase 2 Results
Via
News Direct
BioRestorative (NASDAQ: BRTX) Ramps Up Production In Anticipation Of Positive Phase 2 Results
February 03, 2023
By Julian Richard, Benzinga
Via
TheNewswire.com
BioRestorative (NASDAQ: BRTX) Ramps Up Production In Anticipation Of Positive Phase 2 Results
February 03, 2023
Chronic lumbar disc disease (cLDD) is a debilitating condition affecting millions of people worldwide. It is characterized by back pain, stiffness, and restricted movement due to damage to the bony...
Via
Benzinga
2022 Was A Year Of Growth, Funding, And Positive Results For BioRestorative Therapies
January 26, 2023
By Faith Ashmore, Benzinga
Via
TheNewswire.com
Topics
Intellectual Property
Exposures
Intellectual Property
2022 Was A Year Of Growth, Funding, And Positive Results For BioRestorative Therapies
January 26, 2023
2022 Was A Year Of Growth, Funding, And Positive Results For BioRestorative Therapies
Via
News Direct
2022 Was A Year Of Growth, Funding, And Positive Results For BioRestorative Therapies
January 25, 2023
BioRestorative Therapies Inc. (NASDAQ: BRTX) (“BioRestorative”) may have had a successful year of novel drug development.
Via
Benzinga
BioRestorative Therapies Announces SBIR Phase I Grant to Explore the Therapeutic Effects of ThermoStem® Targeting Polycystic Ovary Syndrome as an Indication
December 06, 2022
From
BioRestorative Therapies, Inc
Via
GlobeNewswire
EXCLUSIVE: BioRestorative Secures Funding Support For Programs Against Polycystic Ovary Syndrome
December 06, 2022
BioRestorative Therapies Inc (NASDAQ: BRTX) has received a Small Business Innovation Research (SBIR) Phase I grant from the Eunice Kennedy Shriver National Institute Of Child Health & Human Development...
Via
Benzinga
BioRestorative Therapies Enters Agreement with Regenexx, Granting BRTX Exclusive License Rights for Intellectual Property Related to the Development and Commercialization of its BRTX-100® Disc Program to Treat Chronic Lumbar Disc Disease
December 05, 2022
From
BioRestorative Therapies, Inc
Via
GlobeNewswire
EXCLUSIVE: BioRestorative Therapies Gets Exclusive License Rights From Regenexx For Development Of BRTX-100 Disc Program To Treat Chronic Lumbar Disc Disease
December 05, 2022
BioRestorative Therapies, Inc (NASDAQ: BRTX), a stem cell-based therapies clinical-stage company, forged an agreement with Regenexx, LLC, under which BRTX gets exclusive license rights for intellectual...
Via
Benzinga
BioMedNewsBreaks – BioRestorative Therapies Inc. (NASDAQ: BRTX) to Participate at RHK Capital Disruptive Growth Conference
November 29, 2022
Via
Investor Brand Network
12 Health Care Stocks Moving In Wednesday's Intraday Session
November 23, 2022
Via
Benzinga
BioRestorative Therapies to Participate at the RHK Capital Disruptive Growth Conference on December 5-6, 2022
November 16, 2022
From
BioRestorative Therapies, Inc
Via
GlobeNewswire
Chronic Obstructive Pulmonary Disease (COPD) Market Expected to Reach $25 Billion By 2027
November 15, 2022
EQNX::TICKER_START (OTCQB:OCEL),(NASDAQ:BRTX),(NASDAQ:MDXG),(NYSE:NNVC),(NASDAQ:VCEL) EQNX::TICKER_END
Via
FinancialNewsMedia
The NIH Has Given BioRestorative Therapies A Stamp Of Approval
November 10, 2022
By Faith Ashmore, Benzinga
Via
News Direct
The NIH Has Given BioRestorative Therapies A Stamp Of Approval
November 10, 2022
BioRestorative Therapies Inc. (NASDAQ: BRTX) is working on products that may be solutions to conditions that affect millions of Americans with lower back pain and diabetes.
Via
TheNewswire.com
The NIH Has Given BioRestorative Therapies A Stamp Of Approval
November 09, 2022
BioRestorative Therapies Inc. (NASDAQ: BRTX) is working on products that may be solutions to conditions that affect millions of Americans with lower back pain and diabetes.
Via
Benzinga
See What's Next For The Regenerative Medicine Field -- BioRestorative Intends to Lead The Pack In Stem Cell Therapies!
October 28, 2022
While stem cell therapy has always been a more controversial topic, as the general public has gained more knowledge on the practice and induced pluripotent stem (iPS) cells have gained traction in...
Via
Benzinga
BioRestorative Therapies CEO Lance Alstodt to be Interviewed on Famela and Friends Talk Radio Show
October 20, 2022
From
BioRestorative Therapies, Inc
Via
GlobeNewswire
A Look At Some Of The Companies Innovating In the Cutting-Edge Regenerative Medicine Field
October 14, 2022
Biotechnology companies have broken many medical barriers in the past 40 years, harnessing the technological revolution to bring innovative solutions to medical problems.
Via
TheNewswire.com
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.